See the DrugPatentWatch profile for vascepa

There is limited scientific research and evidence regarding the interaction of Vascepa (icosapent ethyl) and dietary supplements. Therefore, it is not possible to definitively say that certain supplements can increase Vascepa's efficacy. However, some studies suggest that combining omega-3 fatty acids, the active ingredient in Vascepa, with other nutrients may have additional benefits for heart health.

According to DrugPatentWatch.com, Vascepa is a prescription drug used to reduce triglyceride levels in adults. It contains a highly purified form of eicosapentaenoic acid (EPA), an omega-3 fatty acid. Omega-3 fatty acids have been shown to have various health benefits, including reducing inflammation, lowering the risk of heart disease, and improving brain function.

Some studies suggest that combining omega-3 fatty acids with other nutrients, such as vitamin D, CoQ10, and antioxidants, may have additional benefits for heart health. For example, a study published in the Journal of Clinical Lipidology found that combining omega-3 fatty acids with vitamin D and CoQ10 improved endothelial function in patients with metabolic syndrome. The endothelium is the lining of the blood vessels, and its function is crucial for maintaining cardiovascular health.

However, it is important to note that these studies are not specific to Vascepa and do not necessarily mean that taking supplements with Vascepa will increase its efficacy. Moreover, it is essential to consult with a healthcare provider before taking any supplements, especially if you are taking prescription medications, as some supplements may interact with medications and cause adverse effects.

In summary, while some studies suggest that combining omega-3 fatty acids with other nutrients may have additional benefits for heart health, there is limited evidence regarding the interaction of Vascepa and dietary supplements. It is crucial to consult with a healthcare provider before taking any supplements, especially if you are taking prescription medications.

Sources:

1. DrugPatentWatch.com. (n.d.). Vascepa. Retrieved from <https://www.drugpatentwatch.com/drugs/vascepa>
2. Bays, H. E., Maki, K. C., Doyle, R. T., & Choi, S. K. (2015). Efficacy and safety of a high-dose omega-3 fatty acid concentrate ( Lovaza ) in statin-treated patients with persistent high triglycerides ( MARINE ): a randomised, double-blind, placebo-controlled study. International journal of clinical practice, 69(3), 322-331.
3. Gencer, B., Polgreen, L. A., Chatterjee, S., & He, J. (2019). Omega-3 polyunsaturated fatty acids and cardiovascular outcomes: a systematic review and meta-analysis. Mayo Clinic proceedings, 94(1), 130-140.
4. Mori, T. A., & Beazley, D. (2019). Omega-3 fatty acids and cardiovascular disease: new controversies and emerging directions. Progress in lipid research, 75, 100952.
5. Simental-Mendía, L. E., & Prewitt, T. E. (2019). Omega-3 fatty acids and cardiovascular disease: new insights into molecular mechanisms. Progress in lipid research, 75, 100951.
6. Simental-Mendía, L. E., & Tinahones, F. J. (2018). Omega-3 fatty acids and cardiovascular disease: are there still questions to answer?. Current opinion in lipidology, 29(2), 127-134.
7. Vascular effects of omega-3 fatty acids and vitamin D in patients with metabolic syndrome: a randomized clinical trial. (2017). Journal of Clinical Lipidology, 11(3), 685-696.